Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

by Ysios Capital

Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un compuesto natural obtiene resultados ...

by Universidad Autónoma de Madrid

El tratamiento experimental con el flavonoide 7,8 dihidroxiflavona com...

Photos Stream